NCT02827968View on ClinicalTrials.gov

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 13, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

December 31, 2020

Conditions

Solid Tumors

Interventions

DRUG

KN035

KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.

Trial Locations (2)

47905

Horizon Oncology Research, INC, Lafayette

TX 78229

South Texas Accelerated Research Therapeutics, San Antonio

All Listed Sponsors

lead

3D Medicines (Sichuan) Co., Ltd.

INDUSTRY

NCT02827968 - Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter